High call volumes
Our member and provider services may be experiencing higher than normal call volumes from 12/22/25-1/9/26 due to a large number of staff being out of office. We encourage you to utilize alternative forms of communication including secured messaging through online Member Services and Availity Essentials Provider Portal.
BCBSND district offices will be closed to the public on Friday, Dec. 26.
This includes Bismarck, Grand Forks, Jamestown and Minot. Need help? We’re here for you! Log in at BCBSND.me or call 844-363-8457.
We are unable to accept walk-ins on Friday, Dec. 26, and Friday, Jan. 2., due to short staffing.
Impacting our Commercial line of business only.
As outlined in our April 10, 2025, HealthCare News article Coming Soon: Stelara Biosimilar Product Changes, effective July 1, 2025, Selarsdi (ustekinumab-aekn), Steqeyma (ustekinumab-stba), and Yesintek (ustekinumab-kfce) will be the preferred Stelara biosimilar products on all Blue Cross Blue Shield of North Dakota (BCBSND) formularies. Stelara will be removed from formularies and will be a non-preferred medication. Current coverage for Stelara will remain the same through June 30, 2025.
Members who are part of the Exclusive Specialty Pharmacy Network with Accredo and Prime Therapeutics Pharmacy (PTP) will have access to Selarsdi at PTP. Steqeyma and Yesintek can be filled at either Accredo or PTP.
Members who are part of the Limited Preferred Specialty Network should check with the in-network specialty pharmacy of choice prior to sending a biosimilar prescription.
Questions?
Refer to the full article at Coming Soon: Stelara Biosimilar Product Changes. Providers can also contact PTP at 800-424-1708 or BCBSND Provider Service Center at 800-368-2312.
